Oncologic Disorders Clinical Trial
Official title:
The Right to be Forgotten in the AYA Population: Patients' Experience and Perspectives (Diritto All'Oblio)
Cancer survivors experience a form of social discrimination that is described in numerous areas such as private life, educational and work paths and the achievement of personal goals. Starting from this scenario, more and more national legislative initiatives are emerging to reconcognize the right to be forgotten, defined as the right not to have to report one's, resolved, oncological disease in contact with institutions such as insurance companies, banks or others. The issue of the right to be forgotten is current and new, primarily in the AYA (adolescents and young adults) population. The purpose of this study is to explore and describe the experience of adolescents and young adults affected by previous oncological disease with respect to the issue of the right to be forgotten. In particular, focusing on: - awareness (knowledge of the issue); - significance attributed and subjective perception; - implications/fallouts perceived or experienced on one's present and future history.
Status | Recruiting |
Enrollment | 60 |
Est. completion date | November 16, 2024 |
Est. primary completion date | November 16, 2024 |
Accepts healthy volunteers | |
Gender | All |
Age group | 20 Years and older |
Eligibility | Inclusion Criteria: - Age at diagnosis between (or equal to) 15 and 39 years; - patients not in active phase of treatment; - at least 5 years elapsed since diagnosis; - comprehension and written expressive ability of the Italian language. - subscription informed consent to the study. Exclusion Criteria: NA |
Country | Name | City | State |
---|---|---|---|
Italy | Centro di Riferimento Oncologico (CRO) di Aviano - IRCCS | Aviano | Pordenone |
Italy | IRCCS Ospedale Policlinico San Martino | Genova | |
Italy | Fondazione IRCCS Istituto Nazionale Tumori | Milano | |
Italy | Istituto Europeo di Oncologia IRCCS | Milano | |
Italy | Azienda Ospedaliero-Universitaria di Modena | Modena | |
Italy | Università degli studi di Milano - Bicocca | Monza | |
Italy | Università di Palermo | Palermo | |
Italy | IRCCS, Ospedale Bambino Gesù | Roma | |
Italy | Ospedale Regina Margherita | Torino |
Lead Sponsor | Collaborator |
---|---|
Centro di Riferimento Oncologico - Aviano |
Italy,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Frequency of participants citing words attributable to the topic of awareness in the text with the aim to explore the experience of adolescents and young adults with prior cancer with respect to the issue of the right to be forgotten. | Frequency with which words attributable to the topic of awareness are expressed in the text | up to 1 year | |
Primary | Frequency of participants citing words attributable to the thematic area that delineate the architecture of the text about meaning and subjective perception of the right to be forgotten. | Frequency of participants citing words attributable to the thematic area that delineate the architecture of the text about meaning and subjective perception of the right to be forgotten. | up to 1 year | |
Primary | Frequency of participants citing words attributable to implications/implications perceived or experienced on one's present and future history with respect to the issue of the right to be forgotten. | Frequency of participants citing words attributable to implications/implications perceived or experienced on one's present and future history with respect to the issue of the right to be forgotten. | up to 1 year | |
Secondary | Frequency of patients with information that can lead to the recognition of the right to be forgotten primarily in the AYA population | Frequency of patients with information that can lead to the recognition of the right to be forgotten primarily in the AYA population measured through indicators that identify this argumentative junction in the text | up to 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05132998 -
Impact of a Comprehensive Cardiac Rehabilitation Program Framework Among High Cardiovascular Risk Cancer Survivors
|
N/A | |
Completed |
NCT01210716 -
Evaluation of Therapeutic Plasma Exchange (TPE) Procedure Using the AMICUS Device
|
Phase 3 | |
Completed |
NCT05478733 -
Study of Factors Associated With Significant MYoCArdian Uptake on 68Ga-DOTATOC PET Scans for Oncology
|
||
Terminated |
NCT03978312 -
Nutrition Health Literacy of Cancer Patients and Their Support Networks.
|
||
Not yet recruiting |
NCT04142463 -
Collaborative Network to Take Responsibility for Oral Anticancer Therapy 2
|
N/A | |
Completed |
NCT04420039 -
Plastic Stent Within a Lumen-Apposing Stent for Malignant Biliary Obstruction
|
||
Completed |
NCT03416465 -
Place of General Medical During Oncology Care Management
|
||
Withdrawn |
NCT03041571 -
Impact of Early Implementation of Narrative Medicine Techniques on Patient Centered Attitudes of Medical Students
|
||
Completed |
NCT02484053 -
Rapid Infusion Rituximab, Hematologic, Oncologic, and Rheumatologic Disorders
|
Early Phase 1 | |
Completed |
NCT03030248 -
Vancomycin for C Difficile NAAT+/EIA- Hematology Oncology Patients
|
Phase 2 | |
Not yet recruiting |
NCT03168048 -
Oncologic Therapy Support Via Means of a Dedicated Mobile App
|
N/A | |
Completed |
NCT03426553 -
Clinical Use of Pathogen Reduced Red Blood Cell Suspension
|
Phase 3 | |
Completed |
NCT04271670 -
Effect of Warm Water Footbaths With Added Ginger or Mustard Powder on Psychosocial Parameters in Patients With an Oncological Disease
|
N/A | |
Active, not recruiting |
NCT04842214 -
Disease Course in Oncological Patients During Inpatient Rehabilitation and After Three Months Follow-up
|
||
Completed |
NCT03272646 -
Prognostic Performance of the Naples Prognostic Score
|
N/A | |
Terminated |
NCT02285296 -
The Needs and Burden of Family Caregivers of Older Adults With Cancer
|
N/A | |
Completed |
NCT04918888 -
COVID-19 Vaccination in Oncologic Patients
|
||
Recruiting |
NCT05769868 -
Efficacy of Esmolol in the Identification of Cardiovascular Disorders by Cirrhosis, Diabetes Mellitus and Cardiotoxic Treatments
|
Phase 3 |